sansrosa articles ↓

In an encouraging sign that Sansrosa is slowly but surely progressing towards FDA approval, the clinicaltrials.gov register lists Galderma recruiting for a dose-finding trial for a product code named CD07805/47. The aim of this trial is show which strength is the most suitable for general use. Trial participants will be using one of 4 different strengths: 0.07%, 0.18%, %0.50 or effectively %0 contained …

The Dermatology Times is running an article highlighting the novel and unlikely rosacea treatments based on a nasal decongestant and a glaucoma treatment. They of course are referring to Oxymetazoline and Brimonidine. The article mentions the positive results from the “most recent research” on Brimonidine ; In the most recent research, a double-blind study for Galderma, a 1 g application …

A new sansrosa patent application has appeared, and from it was can see clearly what formula will be used for the sansrosa gel and sansrosa cream formulations. We don’t know the official name for the product yet, but it seems to make sense to me to call the product Sansrosa Gel and Sansrosa Cream.

Those following the development of sansrosa closely will be encouraged by this …

We know from patent filings that the active ingredient in the in-development sansrosa product is brimonidine tartrate. This is also the active ingredient in Alphagan P, a treatment for glaucoma.

Alphagan P 0.1%, is known as an alpha2-adrenergic receptor agonist, and is used to lower intraocular pressure and reduce ocular hypertension. Around 10-20% of users of Alphagan P experience adverse side …

Dermatology times has posted some short items that may be worth reading. Most of these topics are not new to regular readers of Rosacea News, but it is good to see at least some others covering them as well. One article talks about how Galderma/Collagenex is excited about new possible drugs. It doesn’t directly name the Sansrosa product, but it does have a …